Homologous recombination status drives disease-free survival in patients with advanced ovarian cancer undergoing hyperthermic intraperitoneal chemotherapy at the time of interval debulking surgery
Addition of paclitaxel to cisplatin at the time of IDS with HIPEC had no effect on <i>peri</i>-operative morbidity. No differences in DFS were seen between treatment groups. HRD group had a significantly longer DFS, when compared to HRP. Tumor genetics and HR status likely drive response to treatment in advanced ovarian cancer.
Authors
- SeungYong Han (ORCID: https://orcid.org/0000-0002-8389-2766)
- Scott E. Lentz (ORCID: https://orcid.org/0000-0002-9435-2570)
- Allison E. Axtell
- Brandon I. Ing
- Khrystyna Levytska (ORCID: https://orcid.org/0000-0003-4214-6799)
- M. Amneus
Institutions
- Cedars-Sinai Medical Center (US)
- Kaiser Permanente (US)
- Los Angeles Medical Center (US)
- Kaiser Permanente West Los Angeles Medical Center (US)
Publication Details
- Journal
- Gynecologic Oncology Reports
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1016/j.gore.2025.101981
- Primary Topic
- Intraperitoneal and Appendiceal Malignancies
- Type
- article
- Field-Weighted Citation Impact
- 0.00